← SynDRA
CLADRIBINE
SynDRA canonical compound SYN0014091 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | ADA |
|---|
| Mechanism of action | Ribonucleoside reductase inhibitor |
|---|
| Indication | hairy cell leukemia |
|---|
| Disease area | hematologic malignancy |
|---|
All known targets
- ADA
- Adora1
- Adora2a
- DCK
- PDE4A
- PNP
- POLA1
- POLE
- POLE2
- POLE3
- POLE4
- RRM1
Mechanisms of action (all sources)
- Adenosine deaminase inhibitor
- Ribonucleoside reductase inhibitor
- ribonucleotide reductase inhibitor
- ADA INHIBITOR
Drug classes
- Purine Antimetabolite
- Antineoplastic Agents
- Immunologic Factors
- Immunosuppressive Agents
ATC classes
- L01B · ANTIMETABOLITES
- L04A · IMMUNOSUPPRESSANTS
Cross-references
Synonyms
- mavenclad
- litak
- cladarabine
- leustatin
- Cladribina
- 2-cda
- Cladaribine
- NSC-05014
- NSC-105014
- NSC-105014-F
- RWJ-26251
- Leustat
- Leustatin
- Litak
- Mavenclad
- Chlorodeoxyadenosine
- Cladarabine
- Cladribinum
- CldAdo
- Movectro;Mylinax
- CL9
- Leustatin (TN)
- Cladribine [USAN:INN:BAN]
- RWJ-26251-000
- Cladribine (JAN/USAN/INN)
- Leustatin, 2-chlorodeoxyadenosine, Cladribine
- Adenosine, 2-chloro-2'-deoxy
- (2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol
- 2-Chlorodeoxyadenosine
- 2'-Deoxy-2-chloroadenosine
- 2-CdA
- 2-Chloro-2'-deoxy-beta-adenosine
- 2-Chloro-2'-deoxyadenosine
- 2-Chloro-6-amino-9-(2-deoxy-beta-D-erythropentofuranosyl)purine
- 2-chloro-6-amino-9-(2-deoxy-beta-D-erythro-pentofuranosyl)purine
- 2-chloro-deoxyadenosine
- 2 Chlorodeoxyadenosine
- 2CdA
Reported adverse events
- Teratogenicity
- Headache
- Hypersensitivity
- Infection
- Insomnia
- Alopecia
- Arthralgia
- Bronchitis
- Depression
- Hypertension
- Lymphopenia
- Nausea
Look up CLADRIBINE in the interactive SynDRA portal →